This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $501,011.00 to the University of North Carolina at Chapel Hill to conduct research on biodegradable polymeric microparticles comprised of acetalated dextran and their ability to induce immune tolerance. The goal is to develop an antigen-specific tolerance therapy for autoimmune diseases, an alternative to general...
This federal Project Grant award for $246,623.00 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports research at New York University School of Medicine to study the molecular control of tolerogenic dendritic cell function. The research aims to characterize the dendritic cell subset responsible for maintaining T cell tolerance, including investigating aberrant cytokine...
The University of Chicago was awarded a $506,394 Project Grant by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) on January 24, 2025. The grant supports research to define the mechanisms by which bacterial cholesterol-dependent cytolysins can reorganize host cell organelles and activate the NLRP3 inflammasome signaling pathway, which plays a critical role in the immune response to bacterial infections. The research aims to...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $555,120 to the University of Oklahoma Health Sciences Center to conduct research on the interaction between the nervous and immune systems. The research aims to elucidate how adrenergic nerves in lymph nodes communicate with T cells and stromal cells to promote adaptive immune responses, such as the generation of...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $150,921 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Rector & Visitors of the University of Virginia (UVA) to investigate the interplay between membrane rafts and biomolecular condensates in regulating T cell activation. The goal is to provide evidence and mechanistic insights on how these two cellular structures mutually regulate to tune T cell signaling, which can...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $769,414 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The University of Iowa. The grant, awarded on July 9, 2025, will support research investigating how the cellular protein SAMHD1 regulates innate immune responses and HIV-1 gene expression in macrophages. The research aims to define the mechanisms by which SAMHD1 suppresses type I interferon induction and NF-kB activation...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $229,411 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to Northwestern University to investigate Neisseria gonorrhoeae double-stranded bacteriophage. The research aims to determine whether one or more phage islands can produce phage, explore the regulation of two essential LexA orthologs, and assess whether these phage(s) can infect Neisseria strains or species. This project builds upon the...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $3,248,576 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of California, Davis. The grant, awarded on July 25, 2025, will fund research to understand the cross-protective efficacy of the recently FDA-approved IXCHIQ live attenuated chikungunya virus vaccine against other alphavirus species, assess the vaccine's infectivity and transmissibility in mosquitoes, and...
This Project Grant award of $1,454,386.00 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports fundamental research to better understand the epigenetic regulation of the HIV-1 viral RNA cap. The research aims to define the structural basis of HIV cap hypermethylation and its linkage to modulating host innate immune signaling, with the goal of developing new treatments to neutralize deleterious...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $152,656 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Colorado-Denver. The grant, titled "Synaptopodin and Its Role in Shigella flexneri Intercellular Spread," will fund research to investigate the molecular mechanisms by which the protein synaptopodin promotes the ability of the Shigella bacteria to spread between cells, a critical process for...